Renovo
CompanyUnited Kingdom
Renovo develops 2 assets, the furthest approved (estradiol in atrophic vaginitis). Mostly small molecule acting on ESR2, inflammation and ESR1; based in the United Kingdom.
- Assets
- 2
- Furthest
- Approved
- Trials
- 2
- Signals
- 0
Pipeline
2Estrogen receptor agonist for hormone replacement
ApprovedSmall moleculeESR2Inflammationatrophic vaginitishypogonadism
Estrogen receptor agonist for hormone replacement
ApprovedSmall moleculeESR2Inflammationatrophic vaginitishypogonadism
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms6
- Trials2
- Similar companies6
Updated 7 Oct 2026 · 118 sources